Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 176.75 GBp
Change Today -3.25 / -1.81%
Volume 111.9K
As of 8:44 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

181.50 GBp
Previous Close
180.00 GBp
Day High
181.50 GBp
Day Low
176.50 GBp
52 Week High
05/28/15 - 182.00 GBp
52 Week Low
10/16/14 - 113.75 GBp
Market Cap
Average Volume 10 Days
0.0094 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc researches, develops, and commercialises novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company offers ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; Extraneal for the treatment of peritoneal dialysis; Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); and AirFlusal Forspiro for the treatment of asthma and COPD, as well as Asmasal and Asmabec for the treatment of asthma. Its full development stage products include VR315, VR506, and VR632 for the treatment of asthma. The company’s Phase III clinical stage products include NVA237 and QVA149 for the treatment of COPD; VR475 for the treatment severe adult asthma; and VR876 for the treatment of pulmonary hypertension. Its Phase II clinical stage products comprise VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; VR736 for the treatment severe influenza; and SB010 for the treatment of asthma and other respiratory diseases. The company’s Phase I clinical stage products include VR475 for the treatment severe adult asthma; VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases; and VR611 for the treatment of airways inflammatory and chronic cough diseases. The company also provides drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to enhance the performance of DPI products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides Gryohaler, lever-operated, open-inhale-close, AKITA Jet, APIXNEB, and FOX devices. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 674.0K GBP
Chief Operations Officer and President of US ...
Total Annual Compensation: 482.0K GBP
Compensation as of Fiscal Year 2014.

vectura group plc (VEC) Key Developments

Vectura Group plc Reports Audited Consolidated Preliminary Earnings Results for the Year Ended March 31, 2015

Vectura Group plc reported audited consolidated preliminary earnings results for the year ended March 31, 2015. For the year, the company reported revenue of £58 million against £36.5 million a year ago. Operating loss was £7.0 million against £6.2 million a year ago. EBITDA was £16.2 million against £5.2 million a year ago. Loss before taxation was £6.2 million against £4.8 million a year ago. Profit after taxation attributable to equity holders of the company was £3.7 million against loss of £2.3 million a year ago. Loss per share basic and diluted was 0.9 pence against 0.7 pence a year ago. Adjusted earnings per diluted share were 3.9 pence compared to 1.59 pence a year ago. Net cash inflow from operating activities was £8.0 million against outflow of £0.7 million a year ago. Purchases of property, plant and equipment was £1.4 million against £2.3 million a year ago.

Vectura Group plc, 2015 Earnings Call, May 20, 2015

Vectura Group plc, 2015 Earnings Call, May 20, 2015

Vectura Group plc Intends to Close Gemünden Site, Germany, Effective by March 2016

Vectura Group plc announced its intention to close its site in Gemünden, Germany, effective by March 2016. The Gemünden site was acquired by Vectura as part of the acquisition of Activaero GmbH in March 2014 and is currently involved in the production of the company's nebuliser devices, supporting clinical trials and marketing of the devices. In order to improve manufacturing efficiencies, all activities currently carried out in Gemünden will be transferred to Vectura's facilities in Gauting, Germany, Chippenham UK and Cambridge UK, and to a contract manufacturing organization for any commercial production. As a result, the company will close the site by March 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 176.75 GBp -3.25

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VEC.
View Industry Companies

Industry Analysis


Industry Average

Valuation VEC Industry Range
Price/Earnings 100.0x
Price/Sales 13.0x
Price/Book 3.4x
Price/Cash Flow 30.8x
TEV/Sales 13.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at